Group 1: Business Environment Optimization - The time to open a restaurant has been reduced from 37 days to 15 days, and the number of documents required for business information changes has been streamlined from 23 to 6 [1] - Since the beginning of the "14th Five-Year Plan," there has been a net increase of 19.999 million enterprises and 33.946 million individual businesses in China [2] - The State Administration for Market Regulation has implemented the "Fair Competition Review Regulations" to address issues such as "malicious competition" in investment promotion and has eliminated 4,218 policies that hinder the flow of resources [2][3] Group 2: Consumer Rights Protection - During the "14th Five-Year Plan," the market regulation departments handled 89.028 million complaints, recovering economic losses of 21.71 billion yuan for consumers [3] - The national consumer association received 5.749 million complaints, recovering 5.78 billion yuan in economic losses [3] - The State Administration for Market Regulation has conducted nationwide actions to destroy counterfeit and inferior goods, covering over 200 categories with a total value of 2.79 billion yuan [3] Group 3: Platform Economy Regulation - The platform economy is undergoing a critical transformation, with new risks such as algorithm abuse and competition disorder emerging [4] - Since the "14th Five-Year Plan," the State Administration for Market Regulation has deleted 4.541 million pieces of illegal product information and handled 105,000 internet-related cases [4] - Future efforts will focus on enhancing regulatory frameworks for the platform economy while promoting healthy development [4] Group 4: Pharmaceutical Industry Development - A total of 204 innovative drugs and 265 innovative medical devices have been approved since the "14th Five-Year Plan," with 50 innovative drugs approved in the first seven months of this year [6] - The pharmaceutical industry in China ranks second globally, with approximately 30% of innovative drugs under research worldwide [6] - The National Medical Products Administration is supporting the high-quality development of the pharmaceutical industry through various expedited approval channels [6][7]